Introduction: The eighth edition of the TNM staging system included the proposal that the T descriptor be determined according to the invasive component, excluding lepidic component, for nonmucinous lung adenocarcinomas. We sought to conduct a clinicopathologic comparative analysis of the newly proposed classification using invasive size versus total tumor size.
Introduction
Following the results of the National Lung Screening Trial, which showed that screening with low-dose computed tomography (CT) reduces mortality from lung cancer, the detection of early-stage lung cancer has been expected to increase. 1 In 2016, using survival data from a multinational cohort of patients with NSCLC, the International Association for the Study of Lung Cancer (IASLC) refined their classification of early-stage nodenegative lung cancers less than or equal to 5 cm as follows: IA ( 3 cm) and IB (>3 to 5 cm) in the seventh edition of the TNM classification became IA1 ( 1 cm), IA2 (>1 to 2 cm), IA3 (>2 to 3 cm), IB (>3 to 4 cm), and IIA (>4 to 5 cm) in the eighth edition. 2 Furthermore, the eighth edition addressed the correlation between radiologic part-solid nodules and the histologic components of nonmucinous lung adenocarcinomas (ADCs) and proposed the use of invasive size, rather than total size, for the T descriptor for nonmucinous lung ADCs with a lepidic component. 3 These changes follow previous efforts to achieve better prognostic stratification in lung ADC, the most common histologic subtype of NSCLC. In 2011, a multidisciplinary group of experts from the IASLC, American Thoracic Society, and European Respiratory Society proposed a new classification of lung ADC that included two new subtypes: ADC in situ (AIS) and minimally invasive ADC (MIA). 4 The authors proposed that histologic patterns should be recorded in 5% increments and, on this basis, the predominant histologic pattern (lepidic, acinar, papillary, micropapillary, or solid) determined. In 2013, the Fleischner Society largely based their recommendations for the management of subsolid pulmonary nodules detected by CT scan on this histologic classification system. 5 In 2015, the WHO adopted the histologic classification system following validation of independent cohorts. [6] [7] [8] [9] The TNM staging system remains the most useful tool for determining treatment options for patients with lung cancer. 2 Tumor size is a key element of TNM staging, and the available evidence suggests that, for lung ADC tumors, invasive size is a better predictor of outcomes than total size. 6, [10] [11] [12] Recently, Aokage et al. 13 analyzed a cohort of patients with resected stage I-IV NSCLC using both the seventh and eighth editions of the TNM classification. For staging of nonmucinous lung ADCs with a lepidic component, the T descriptor was determined by total size when the seventh edition was used and invasive size when the eighth was used; comparison revealed good correlation between solid size on CT and invasive size on pathologic assessment. In addition, concordance probability estimates and Akaike's information criterion values for overall survival were higher for the eighth edition than the seventh edition.
To date, no study has investigated the impact of the changes to the definitions of T1 (a, b, and c) and T2 nonmucinous lung ADCs or compared the effect on prognosis of using invasive (i) versus total size (t) for the T descriptor.
In this study, we performed a clinicopathologic comparative analysis of total versus invasive size in nonmucinous lung ADCs with the goal of determining whether the use of invasive size improves prognostic discrimination when using the eighth edition of the TNM classification.
Methods

Patient Cohort
This retrospective study was approved by the Institutional Review Board at Memorial Sloan Kettering Cancer Center (MSK). All patients diagnosed with solitary lung ADC who had undergone surgical resection at MSK between January 2000 and December 2014 were reviewed. Patients who had undergone lung resection for primary lung ADC with pathologic stage (p-Stage) I-IIA (based on total tumor size) were included. Patients who had received induction therapy, had multiple nodules, had lung cancer within the preceding 2 years, had positive surgical margins, or had concurrent disease progression were excluded from analysis, as were patients with a histologic diagnosis of AIS, MIA, invasive mucinous ADC, or colloid predominant ADC ( Supplementary Fig. 1 ). Patient demographic information was obtained from the MSK Thoracic Surgery Service's prospectively maintained lung cancer database. Data on clinical variables and follow-up information were obtained by reviewing patient medical records.
Recurrence and Lung Cancer-Specific Death as Endpoints
Postoperative lung cancer surveillance was performed in accordance with National Comprehensive Cancer Network guidelines.
14 During the first 2 years after surgery, each patient received a physical examination, interval history review, and chest/upper abdomen CT scan, with or without contrast, every 6 to 12 months. Follow-up visits and surveillance CT scans were performed yearly after the first 2 years.
The study endpoints were recurrence and lung cancer-specific death. All recurrences were confirmed by clinical, radiologic, and pathologic assessment. 15 In cases where a new tumor developed in the lung or pleura and a biopsy specimen was available, the histologic profile was reviewed to determine whether the new tumor was a metachronous primary tumor, a recurrence, or a metastasis; this was completed in accordance with the method developed by our group. 16 Lung cancer-specific death was defined as death due to recurrent disease associated with resected lung cancer. 17 
Histologic Evaluation
All available hematoxylin and eosin-stained tumor slides were reviewed by at least two pathologists (S.L., K.K., and W.D.T.), who were blinded to patient clinical outcomes, using an Olympus BX51 microscope (Olympus, Tokyo, Japan) with a standard 22-mm diameter eyepiece. Any discrepancies between the pathologists during assignment of predominant subtypes were later resolved via consensus using a multihead microscope. The percentage of each histologic pattern was recorded in 5% increments. Tumors were classified in accordance with the 2011 IASLC/American Thoracic Society/European Respiratory Society classification and the 2015 WHO classification. 4, 8 Tumors were grouped by histologic grading as low (lepidic), intermediate (papillary or acinar), or high (micropapillary or solid). 18 Visceral pleural invasion (VPI), lymphovascular invasion (LVI), necrosis, and tumor spread through air spaces were also investigated. 19 
Pathologic Assessment of Total and Invasive Tumor Size
Pathologic total tumor size was defined as the maximum diameter of the tumor. Pathologic tumor size was initially assessed by gross measurement using a ruler placed along the tumor in the gross specimen before or after cross-section of the tumor. The initial gross measurement was then re-evaluated by microscopic evaluation to ultimately determine pathologic total tumor size.
Pathologic invasive tumor size was defined as the size of invasive components, excluding lepidic component, on microscopic examination. Although in some cases invasive size could be measured with a ruler in a single focus, in most cases this was not possible, owing to multiple foci of invasion or the presence of invasive areas on multiple slides. Therefore, as proposed by our group in 2014 and included in the 2015 WHO classification, for all cases in this study pathologic invasive tumor size was estimated using the following equation: pathologic invasive size ¼ pathologic total size Â percentage of invasive components/100. p-Stages for all tumors based on total size (t) were reclassified on the basis of invasive size (i). 8, 20 Statistical Analysis
The outcomes of interest -recurrence and lung cancer-specific death -were analyzed in a competingrisk framework. For recurrence, death from any cause without recurrence was considered a competing event.
For lung cancer-specific death, death from causes other than lung cancer or from unknown causes was considered a competing event. The cumulative incidence of recurrence (CIR) and the lung cancer-specific cumulative incidence of death (LC-CID) were used to estimate the probability of recurrence or lung cancer-specific death following surgical resection with curative intent. 21 Patients who did not experience recurrence or die during the study period were censored at the time of the last available follow-up (assessed in April 2017). Differences in CIR or LC-CID between groups were tested using the Gray method. 22 The concordance index (C-index) was assessed to evaluate prognostic discrimination by TNM classification. Statistical analyses were performed using R 3.1.1 (R Development Core Team, Vienna, Austria); the "survival" and "cmprsk" software packages were used in the analyses. All p values were two-sided, and significance was set at 5%. 
Results
Number and Proportion of Patients With Each p-Stage
Clinicopathologic Characteristics by p-Stage(t) and p-Stage(i) Table 1 lists clinicopathologic characteristics stratified by p-Stage(t) and p-Stage(i). Figure 2 Figure 3 shows a comparison of CIR between patients who were classified as the same stage and those who were downstaged when invasive size was used. As shown in the figure, for all stages, patients who were downstaged had a lower risk of recurrence than those whose stage remained the same.
CIR by Same Stage or Downstaged
CIR and LC-CID by p-Stage(t) and p-Stage(i) Prognostic Discrimination (C-index) by p-Stage(t) and p-Stage(i) Table 2 . A higher Cindex indicates better prognostic discrimination. Prognostic discrimination for predicting recurrence was better by p-Stage(i) than p-Stage(t); for predicting lung cancer-specific death, p-Stage(i) was better than p-Stage(t).
Discussion
Our findings in this study validate the use of invasive size, rather than total size, for the T descriptor in nonmucinous lung ADCs with a lepidic component. The strengths of our study are as follows: (1) this is the first study to validate the use of invasive tumor size in a large, uniform cohort of patients with p-Stage I-IIA lung ADC; (2) our investigation revealed that the use of invasive size with the newly proposed staging system provides better stratification of lung cancer-specific outcomes (recurrence and lung cancer-specific death) and prognostic pathologic factors (such as presence of LVI and high-grade subtypes) according to increasing stage; and (3) our prognostic analysis used a competing-risks approach to address the large number of competing events among patients with early-stage lung cancer. 17 When invasive size was used for the T descriptor, more than 20% of patients were downstaged to the most favorable stage (p-Stage IA1); furthermore, the IA1(i) group (n ¼ 389) had a slightly better prognosis than the IA1(t) group (n ¼ 195) (5-year CIR, 11% versus 13%; 5-year LC-CID, 5% versus 7%). Another important finding of our study was the better prognostic stratification when invasive size was used -that is, patients who were downstaged when invasive size was used had fewer recurrences than patients who were not downstaged -especially among patients with p-Stage IIA tumors. In p-Stage I-IIA lung ADCs following marginnegative (R0) resection, the recent National Comprehensive Cancer Network guidelines do not recommend adjuvant chemotherapy, except for those with stage IB (T2aN0) or IIA (T2bN0) tumors with high-risk factors such as greater than 4-cm tumor size, vascular or pleural involvement, wedge resection, or no lymph node 
evaluation.
14 On the basis of the findings of the present study, we suspect that invasive size may be the important factor for consideration of adjuvant chemotherapy, owing to the significant prognostic difference between tumors greater than 4 cm and those 3 to 4 cm in invasive size. However, this requires further investigation in large clinical studies.
Previous studies investigated radiologic-pathologic correlation in lung nodules. [23] [24] [25] [26] Lee et al. 26 investigated 58 lung ADCs using less than or equal to 1.25-mm- (14) 123 (18) 72 (21) 69 (17) 17 (18) 71 (18) 115 (18) 49 (21) 67 (18) (15) 90 (13) 29 (9) 52 (13) 9 (9) 50 (13) 75 (12) 24 (10) 51 (14) 9 (14 (17) 104 (26) 5 (5) 190 (49) 207 (32) 26 (11) 98 (27) (7) 57 (9) 39 (13) 86 (26) 33 (39) 16 (5) 56 (9) 38 (18) 89 (28) 28 (50) (21) 64 (21) 61 (21) 11 (17) 61 (19) 116 (22) 41 (19) 55 (20) 4 (10) KRAS 54 (34) 155 (28) 83 (27) 67 (23) 17 (27) 95 (30) 148 (28) 58 (27) 64 (23) 11 (27) . 26 A recent study investigated radiologic and pathologic correlation in 1792 patients with resected stage I-IV NSCLC and found a strong correlation between consolidation size on thin-section CT and pathologic invasive size (correlation coefficient, 0.83). 13 Consolidation size on preoperative CT may be used to predict pathologic invasive size in clinical practice; however, further investigation (such as a prospective study) is warranted.
One of the potential challenges of using invasive size for staging is reproducibility of the distinction between lepidic and invasive patterns, the kappa value of which was reported to be 0.55 in typical cases and 0.08 in difficult cases. 27 Specifically, it has been reported that it is difficult to differentiate lepidic pattern from papillary or acinar patterns. 28 However, in another study, agreement in the distinction between AIS/MIA and invasive ADC was good, with a kappa of 0.65. 29 In another study, the concordance (using intraclass correlation coefficients) between lepidic predominant subtype and other subtypes was 0.94. 30 In addition, training may increase concordance in histologic subtyping. 28, 31 Although these previous studies that distinguished lepidic "predominant" subtypes (or AIS/MIA) from other invasive morphologic pattern-predominant subtypes showed good results, the reproducibility of determining percentage of lepidic pattern might be more challenging.
It is recommended that mucinous ADCs be measured using total size, regardless of the extent of lepidic component, owing to the lack of validated data supporting the use of invasive size for these tumors 3 ; therefore, we did not include patients diagnosed with invasive mucinous ADC or colloid tumors. In addition, Figure 3 . Cumulative incidence of recurrence between patients who were classified as the same stage and those who were downstaged when invasive size (i) was used, rather than total size (t), for the T descriptor. CIR, cumulative incidence of recurrence; p-Stage, pathologic stage; CI, confidence interval.
mucinous ADCs usually display a consolidation area on CT scan, and radiologic-pathologic correlations between ground-glass and solid patterns on CT and lepidic and invasive patterns on histologic analysis have not been established -although specific radiologic characteristics of mucinous ADC on thin-section CT were reported to be prognostic. 4, 32 More investigation of these tumors is needed.
For pathologic analysis in the present study, we estimated invasive size by multiplying the total tumor size by the percentage of the invasive component. Because, for many tumors, it is impossible to find a single focus of invasion on a single histologic slide, it is essential to have an alternative method. Our results suggest that the approach used in this study is significantly aligned with prognosis. Further investigation is warranted to compare the two methods for determining invasive size -(1) multiplying the total size by the percentage of the invasive component and (2) measuring the greatest diameter of the largest invasive focus using a ruler -especially in cases with multiple areas of invasion.
In conclusion, as proposed in the eighth edition of the TNM staging system, using invasive size rather than total size for the T descriptor achieves better prognostic discrimination by identifying a larger number of patients with a favorable prognosis (p-Stage IA1) -patients who were overstaged using total size. The use of invasive size also provides better stratification of prognoses, which may be useful for determining the most appropriate treatment for patients with early-stage nonmucinous lung ADCs. Table 2 
